Understanding how Rheb regulates cell growth through mTORC1
Molecular mechanism of Rheb-dependent mTORC1 regulation
This study is looking at how a tiny protein called Rheb helps control cell growth by working with another important protein, mTORC1, especially when there are enough nutrients and growth signals around, and it hopes to find new ways to treat diseases like cancer by understanding these processes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11074077 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms by which Rheb, a small GTPase, activates mTORC1, a critical regulator of cell growth and proliferation. The study focuses on how amino acids and growth factors influence the interaction between Rheb and mTORC1 at the lysosomal membrane. By exploring the role of ubiquitination in this process, the research aims to uncover new insights into cellular anabolic processes that could impact various diseases, including cancer. Patients may benefit from a better understanding of these mechanisms, which could lead to novel therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions associated with dysregulated mTORC1 activity, such as certain cancers or metabolic disorders.
Not a fit: Patients with conditions unrelated to mTORC1 regulation or those who do not have any cellular growth abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance or inhibit mTORC1 activity, potentially improving outcomes for patients with conditions related to abnormal cell growth.
How similar studies have performed: Other research has shown promising results in understanding mTORC1 regulation, indicating that this approach has potential for significant advancements in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Inoki, Ken — University of Michigan at Ann Arbor
- Study coordinator: Inoki, Ken
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.